Benjamin Herzberg, MD
Dr. Benjamin Herzberg is a medical oncologist practicing in New York City at the Herbert Irving Comprehensive Cancer Center. He specializes in treating thoracic malignancies, including malignant pleural mesothelioma, non-small cell lung cancer, small cell lung cancer, and thymoma. Dr. Herzberg is committed to providing compassionate, individualized care for his patients. His empathy is driven by cancer having touched his own life.[1]
Education and Career
Dr. Herzberg received his undergraduate degree from Princeton University and a medical degree from the combined Harvard Medical School and MIT Program in Health Sciences and Technology. He also earned a Master of Science degree in the History of Science and Medicine from Imperial College in London. He completed his internship and residency training in Internal Medicine at Massachusetts General Hospital, where he was a Stanbury Physician-Scientist trainee, and a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center, where he was Chief Fellow.[1]
Research
Dr. Herzberg’s research interests are in lung cancer and cancers with special difficulties repairing damage to their DNA. He has developed numerous clinical trials that use novel agents to target DNA repair with hopes of bringing these agents directly to his clinical care of patients. His laboratory work aims to define new vulnerabilities in cancer cells that can be leveraged for more effective, less toxic therapy. His work has received several awards from the National Institute of Health and other organizations.[1]
Active Clinical Trials
Dr. Herzberg has several ongoing clinical trials, including many that are recruiting patients with solid tumors like malignant mesothelioma:[2]
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination with Carboplatin/Gemcitabine/Pembrolizumab in Patients with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF ORAL MRT-2359 IN PATIENTS WITH MYC-DRIVEN AND OTHER SELECTED SOLID TUMORS INCLUDING LUNG CANCER AND DIFFUSE LARGE B-CELL LYMPHOMA
Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)
